Mucin 1 expression correlation with lymph node metastasis and micrometastasis and poor prognosis in patients with esophageal squamous cell carcinomas

Fei Yang¹, Zhe Li², Jing-Bo Shao³, Wei Gao¹, Zhi-Gang Sun⁴

¹Department of Pathology, Jinan Central Hospital Affiliated to Shandong University, Central Hospital Affiliated to Shandong First Medical University, Jinan, China
²Department of Medical Examination, Jinan Central Hospital Affiliated to Shandong University, Central Hospital Affiliated to Shandong First Medical University, Jinan, China
³Weifang Medical University, Weifang, Shandong Province, China
⁴Department of Thoracic Surgery, Jinan Central Hospital Affiliated to Shandong University, Central Hospital Affiliated to Shandong First Medical University, Jinan, China

Submitted: 1 May 2019; Accepted: 17 September 2019
Online publication: 28 October 2019

Arch Med Sci 2023; 19 (3): 638–644
DOI: https://doi.org/10.5114/aoms.2019.89219
Copyright © 2019 Termedia & Banach

Abstract

Introduction: Lymph node metastasis (LNM) and lymph node micrometastasis (LNMM) are prognostic factors in esophageal squamous cell carcinoma (ESCC) patients. The purpose of this research is to investigate whether mucin 1 expression detected by immunohistochemistry in lymph nodes correlates with LNM, LNMM and prognosis in ESCC patients.

Material and methods: There were 92 ESCC patients enrolled in the research, and 1382 lymph nodes were obtained from these 92 patients. All lymph nodes were immunohistochemically analyzed using an anticytokeratin and mucin 1 antibody cocktail.

Results: In the pN1-2 patients’ group, 68 lymph nodes from 15 patients had tumor metastasis. All these 68 tumor metastatic lymph nodes were positive for mucin 1. Mucin 1 was detected in another 231 lymph nodes and among them, 3 (3/231 1.3%) lymph nodes from 2 (2/15 13.3%) patients were positive for mucin 1. In 77 pN0 patients, mucin 1 was detected in 1083 lymph nodes from the 77 patients; 17 (17/1083 1.6%) lymph nodes from 15 (17/1083 1.6%) patients were positive for mucin 1. The 5-year survival rate was 39.1%, and it was significantly related to tumor invasion (pT, p < 0.05), lymph node metastasis (pN, p < 0.01), pTNM stage (p < 0.01) and mucin 1 expression (p < 0.01). Cox regression of multivariate analysis demonstrated that mucin 1 expression and pT were independent prognostic factors.

Conclusions: Mucin 1 expression was related to LNM and LNMM and poor prognosis in ESCC patients. Immunohistochemistry for mucin 1 can be applied for the detection of LNM and LNMM.

Key words: mucin 1, lymph node metastasis, lymph node micrometastasis, esophageal squamous cell carcinoma.

Introduction

Esophageal squamous cell carcinoma (ESCC) is a life-threatening type of skin cancer occurring worldwide including China. So far, radical surgery is a valid therapeutic method. However, the prognosis is still un-
Mucin 1 expression correlation with lymph node metastasis and micrometastasis and poor prognosis in patients with esophageal squamous cell carcinomas

Satisfactory [1, 2]. The ESCC patients’ 5-year survival rate with pathologic lymph node negative metastasis (pN0) could be nearly 70%, but some of the patients still suffer tumor recurrence [3, 4]. Lymph node metastasis (LNM) and lymph node micrometastasis (LNMM) are prognostic factors in ESCC [5]. LNM and LNMM molecular mechanisms in ESCC are not completely clarified. Tumor TNM stage is commonly used in assessing tumor patients’ prognosis, but most of the time we found that TNM stage was not in conformity with the actual prognosis.

With the development of molecular biotechnology, some new ways have been used in tumor prognostic research. Mucin 1 is a cell surface glycoprotein and has been regarded as an epithelial tissue specific marker. Mucin 1 is observed on normal glandular epithelial cells and its number could be significantly increased when the cells become malignant [6, 7]. Some research has shown that mucin 1 was related to poor prognosis of some carcinomas [8–11]. Recently it has been reported that mucin 1 is associated with LNMM, and could exactly be used to estimate LNMM of lung cancer patients who underwent radical surgery [12].

The purpose of our study is to assess whether mucin 1 expression detected by immunohistochemistry in lymph nodes correlates with LNM, LNMM and prognosis in patients with ESCC.

Material and methods

Patients

A total of 92 patients were enrolled in the research, at the Department of Thoracic Surgery, Jinan Central Hospital from January 2009 to December 2013. The eligibility standards were as follows: (1) ESCC was confirmed by curative resection and postoperative pathology for all the subjects. (2) No cervical or supraclavicular lymph node metastasis was found by cervical B ultrasound or preoperative computed tomography (CT). (3) No serious contraindications were found. (4) TNM staging (the 8th edition) was referred to the International Union Against Cancer (UICC) [13]. This research was approved by the Jinan Central Hospital’s Ethics Committee.

Samples and Immunohistochemistry

Overall, 1382 lymph nodes were obtained from the 92 patients in the experimental group. A total of 20 paraesophageal lymph nodes were obtained from 10 benign esophageal disease cases as the control group. To avoid sample heterogeneity, 3 mm thick sections at each level from each paraffin block were used. The first slice was stained with HE. The other was stained with immunohistochemistry. The HE-stained slices were carried out on paraffin-embedded and immunohistochemical reactions. Primary antibodies against mucin 1 (dilution 1:100, Maxim Inc., Fuzhou, China) were used. The immunostained slides were independently evaluated by two of our authors. The diagnostic criteria of LNMM were as below: (1) No tumor cells were observed on the HE stained slices. (2) At least one strongly immunoreactive epithelial cell in the cortex of the lymph node or in the subcapsular sinus was observed ranging from 0.2 mm to 2 mm on the immunohistochemical slices.

Follow-up

The subjects underwent routine examination every 3 months. They received physical examination, chest and abdomen CT, and some of them were also examined by positron emission tomography combined with CT (PET/CT).

Statistical analysis

The χ² test or Fisher’s exact probability test was used to analyze the enumeration data. The Kaplan-Meier method was used to analyze the survival results. The Cox proportional hazard model was used for multivariate analysis. P-values less than 0.05 were considered significant. The statistical data were processed with the SPSS 23.0 software.

Results

Mucin 1 expression in lymph nodes

Mucin 1 was detected in 1382 lymph nodes from 92 patients (Figure 1). In the pN1-2 patients’ group, 68 lymph nodes from 15 patients had tumor metastasis. All the 68 tumor metastatic lymph nodes were positive for mucin 1. The diagnostic sensitivity was 100% (68/68). Mucin 1 was detected in another 231 lymph nodes and among them, 3 (3/231 1.3%) lymph nodes from 2 (2/15 13.3%) patients were positive for mucin 1. In the 77 pN0 patients, mucin 1 was detected in 1083 lymph nodes from the 77 patients; 17 (17/1083 1.6%) lymph nodes from 15 (15/77 19.5%) patients were positive for mucin 1. In the control group, mucin 1 was detected in 20 lymph nodes from the 10 patients. No mucin 1 positive case was observed in the lymph nodes. The above data show that mucin 1 expression in the pN1-2 group was significantly higher than that in the pN0 group (p < 0.01), and was also higher than that in the control group (p < 0.01). There was no significant difference between mucin 1 expression in the pN0 patient group and the control group (p > 0.05).
Correlation between mucin 1 expression and prognosis

After surgery, 61 patients accepted chemotherapy, and 31 patients accepted radiotherapy. The 92 patients' 5-year survival rate was 39.1%, which was significantly related to tumor invasion (pT, p < 0.05), lymph node metastasis (pN, p < 0.01), pTNM stage (p < 0.01) and mucin 1 expression (p < 0.01) (Figure 2, Table I). The 5-year survival rate of the patients with mucin 1 expression in lymph nodes group was significantly lower (10.0% vs. 53.2%; p < 0.01) than in the group without mucin 1 expression. Cox regression of multivariate analysis demonstrated that mucin 1 expression and pT were independent prognostic factors (Table II).

Discussion

Being a transmembrane glycoprotein, mucin 1 is observed in many epithelial cell types [14]. It participates in cell adhesion modulation and protection from infection [15, 16]. Furthermore, mucin 1 could be overexpressed in some kinds of tumors and prevent immunocytes from attacking cancer cells [17]. Previous studies have reported that mucin 1 expression was related to poor prognosis in some cancers [18–21]. A similar tendency has been reported for ESCC [22]. Our previous study showed that both mucin 1 mRNA and protein expression in ESCC tissue was related to tumor invasion, lymph node metastasis, pTNM stage and poor prognosis for ESCC patients [23]. In this study, we investigated mucin 1 expression in lymph nodes in ESCC patients who accepted radical resection using immunohistochemistry. In the pN1-2 patient group, 68 lymph nodes from 15 patients had tumor metastasis. All the metastatic lymph nodes showed mucin 1 expression. None of the mucin 1 was detected in the benign esophageal disease group. Our results provided evidence at the protein level that mucin 1 might be a biomarker for detecting LNM in ESCC.

In this study, we also found mucin 1 expression in the pN0 patient group. It implied that there existed LNMM which was not detected by pathology. So far, no definite gene could predict LNMM. The common markers used to detect LNMM include cytokeratin (CK), carcinoembryonic antigen (CEA), E-cadherin and matrix metalloproteinase (MMP) [24]. The standard diagnostic method of LNMM needs one or a few histopathologic HE stain sections from each lymph node. However, previous studies showed that about 20% of LNMM could not be detected with this method [25]. LNMM is defined as a small metastatic lesion measuring from 0.2 to 2 mm tumor cells in a lymph node, which could not be detected by conventional pathology methods [26]. Several methods of detecting micrometastases are available, including reverse polymerase chain reaction (PCR) and immunohistochemical staining.

Up to now, continuous pathological section has been the most accurate diagnostic method.

Figure 1. Expression of mucin 1 detected by immunohistochemistry. A – In pN1-2 patient group, the tumor metastatic lymph node was positive for mucin 1. B – In pN0 patient group, lymph node was negative for mucin 1. C – In pN0 patient group, lymph node was positive for mucin 1.
Mucin 1 expression correlation with lymph node metastasis and micrometastasis and poor prognosis in patients with esophageal squamous cell carcinomas

For LNMM. However, it is time consuming and complex, so it could not be routinely used in many hospitals. PCR has been used for detecting LNMM. Sensitivity is the greatest superiority of this method. PCR could detect a tumor cell in $1 \times 10^7$ cells [27]. Moreover, even poorly differentiated tumors with tissue-specific proteins unexpressed could also be detected for tumor mRNA expression using the PCR technology. PCR also has a shortcoming: contamination or the presence of a pseudogene might lead to false positives. Target markers’ heterogeneous expression could also cause false negatives. Up to now, pathologic diagnosis is still the gold standard. When using PCR to detect LNMM, a lymph node should be divided in half with one half for PCR and the other for rou-

Figure 2. A – Kaplan-Meier analysis of overall survival. B – Kaplan-Meier analysis of overall survival rate in patients with pT. C – Kaplan-Meier analysis of overall survival rate in patients with pN. D – Kaplan-Meier analysis of overall survival rate in patients with pTNM stage. E – Kaplan-Meier analysis of overall survival rate in patients with mucin 1 expression.
### Table I. Correlation between 5-year survival and clinical features of the 97 patients with esophageal squamous cell carcinoma

| Clinical characteristics | Patients (N = 92) | 5-year survival (%) | P-value |
|--------------------------|------------------|---------------------|---------|
|                          | Patients (n = 36) | Rate (%)            |         |
| Gender:                  |                  |                     | 0.442   |
| Male                     | 73               | 27                  | 37.0    |
| Female                   | 19               | 9                   | 47.4    |
| Age [years]:             |                  |                     | 0.449   |
| ≤ 60                     | 36               | 12                  | 33.3    |
| > 60                     | 56               | 24                  | 42.9    |
| Tumor length [cm]:       |                  |                     | 0.443   |
| < 3                      | 18               | 9                   | 50.0    |
| 3–5                      | 63               | 24                  | 38.1    |
| > 5                      | 11               | 3                   | 27.3    |
| Differentiation:         |                  |                     | 0.102   |
| Well                     | 19               | 11                  | 57.9    |
| Moderately               | 41               | 15                  | 36.6    |
| Poorly                   | 32               | 10                  | 31.3    |
| pT:                      |                  |                     | 0.013   |
| T1                       | 5                | 5                   | 100.0   |
| T2                       | 43               | 19                  | 44.2    |
| T3                       | 44               | 12                  | 27.3    |
| pN:                      |                  |                     | 0.001   |
| –                        | 77               | 35                  | 45.5    |
| +                        | 15               | 1                   | 6.7     |
| pTNM:                    |                  |                     | 0.001   |
| I                        | 13               | 13                  | 100.0   |
| II                       | 65               | 22                  | 33.8    |
| III                      | 14               | 1                   | 7.10    |
| Mucin 1 expression:      |                  |                     | 0.001   |
| –                        | 62               | 33                  | 53.2    |
| +                        | 30               | 3                   | 10.0    |
| Chemotherapy:            |                  |                     | 0.120   |
| –                        | 31               | 17                  | 54.8    |
| +                        | 61               | 19                  | 31.1    |
| Radiotherapy:            |                  |                     | 0.809   |
| –                        | 50               | 21                  | 42.0    |
| +                        | 42               | 15                  | 35.7    |

*P-value: log-rank test.*
Mucin 1 expression correlation with lymph node metastasis and micrometastasis and poor prognosis in patients with esophageal squamous cell carcinomas

Salerno was the first to detect mucin 1 mRNA expression in lymph nodes by RT-PCR and found that mucin 1 mRNA can diagnose LNMM in lung cancer [28]. The sensitivity of mucin 1 detection in diagnosing LNMM was as good as CK as reported in the literatures [29]. Our previous study showed that mucin 1 mRNA can diagnose LNMM in ESCC patients by RT-PCR and the diagnostic sensitivity was 28.1% [30]. In this study, in the group of 77 pN0 patients, mucin 1-positive carcinoma cells were found in 17 (1.6%) of 1083 lymph nodes from 15 (19.5%) patients, showing that LNMMs were found in 15 patients with 17 lymph nodes.

Previous studies have shown that tumor recurrence and poor survival after surgery were correlated with the LNMM detected by IHC or RT-PCR [3–5]. Our data were consistent with their conclusion. The 97 patients’ 5-year survival rate was significantly related to tumor invasion (pT), lymph node metastasis (pN), pTNM stage and mucin 1 expression. Cox multivariate regression analysis was performed to eliminate the impact of mixed factors related to prognosis on statistical analysis, and the results showed that mucin 1 expression and pT were independent relevant factors.

In conclusion, mucin 1 expression was related to LNMM and poor prognosis in ESCC patients. Immunohistochemistry for mucin 1 can be applied for the detection of LNMM and LNMM. Our data demonstrated that mucin 1 was a prognostic marker as well as a molecular target for the effective treatment of ESCC patients.

Acknowledgments

The research was supported by the Second Group of Jinan Science and Technology Development Program (grant no. 201602204).

Conflict of interest

The authors declare no conflict of interest.

References

1. Zhang DW, Cheng GY, Huang GJ, Zhang RG, Liu XY, Mao YS. Operable squamous esophageal cancer: current results from the East. World J Surg 1994; 18: 347-54.
2. Kang K, Huang YH, Li HP, Guo SM. Expression of UCA1 and MALAT1 long-chain non-coding RNAs in esophageal squamous cell carcinoma tissues is predictive of patient prognosis. Arch Med Sci 2018; 14: 752-9.
3. Visbal AL, Allen MS, Miller DL, Deschamps C, Trastek VF, Poirier PC. Iver Lewis esophagogastrectomy for esophageal cancer. Ann Thorac Surg 2001; 71: 1803-8.
4. Eloubeidi MA, Desmond R, Arguedas MR, Reed CE, Wilcox CM. Prognostic factors for the survival of patients with esophageal carcinoma in the U.S.: the importance
of tumor length and lymph node status. Cancer 2002; 95: 1434-43.
5. Matsumoto M, Natsugoe S, Okumura H, et al. Overexpression of vascular endothelial growth factor-C correlates with lymph node micrometastasis in submucosal esophageal cancer. Gastrointest Surg 2006; 10: 1016-22.
6. Hirasewa Y, Kohno N, Yokoyama A, Kondo K, Hiraoka K, Miyake M. Natural autoantibody to MUCIN 1 is a prognostic indicator for non-small cell lung cancer. Am J Respir Crit Care Med 2000; 161: 589-94.
7. Baldus SE, Zirbes TK, Glossmann J, et al. Immuneoreactivity of monoclonal antibody BW835 represents a marker of progression and prognosis in early gastric cancer. Oncology 2001; 61: 147-55.
8. Xu Y, Kimura N, Yoshida R, Lin H, Yoshinaga K. Immunohistochemical study of Mucin 1, Muc2 and human gastric mucin in breast carcinoma: relationship with prognostic factors. Oncol Rep 2001; 8: 60-73.
9. Lee HS, Lee HK, Kim HS, Yang HK, Kim YI, Kim WH. MUCIN 1, MUC2, MUC5AC, and MUC6 expressions in gastric carcinoma: their roles as prognostic indicators. Cancer 2001; 92: 1427-34.
10. Kraus S, Abel PD, Nachtmann C, et al. MUCIN 1 mucin and trefoil factor 1 protein expression in renal cell carcinoma: correlation with prognosis. Hum Pathol 2002; 33: 607-34.
11. Kashiwagi H, Kijima H, Dowaki S, et al. MUCIN 1 and MUC2 expression in human gallbladder carcinoma: a clinicopathological study and relationship with prognosis. Oncol Rep 2001; 8: 485-9.
12. Niu Z, Zhou Q, Sun Z, et al. Detection of mRNA expression of CK-19 and MUCIN 1 gene for diagnosis of lymph node micrometastasis in NSCLC patients by reverse transcriptase-polymerase chain reaction. Zhongguo Fei Ai Za Zhi 2004; 7: 209-13.
13. Amin MB. AJCC Cancer Staging Manual. 8th edition. Springer, Chicago 2017; 185-202.
14. Gendler SJ, Spicer AP. Epithelial mucin genes. Annu Rev Physiol 1995; 57: 607-34.
15. DeSouza MM, Lagow E, Carson DD. Mucin functions and expression in mammalian reproductive tract tissues. Biochem Biophys Res Commun 1998; 247: 1-6.
16. Chervenak JL, Illsley NP. Episialin acts as an antiadhesive factor in an in vitro model of human endometrial-blastocyst attachment. Biol Reprod 2000; 63: 294-300.
17. Brayman MJ, Dharmaraj N, Lagow E, Carson DD. Mucin 1 expression is repressed by protein inhibitor of activated signal transducer and activator of transcription-γ. Mol Endocrinol 2007; 21: 2725-37.
18. Xu Y, Kimura N, Yoshida R, Lin H, Yoshinaga K. Immunohistochemical study of Mucin 1, Muc2 and human gastric mucin in breast carcinoma: relationship with prognostic factors. Oncol Rep 2001; 8: 1177-82.
19. Jing X, Liang H, Hao C, Yang X, Cui X. Overexpression of MUC1 predicts poor prognosis in patients with breast cancer. Oncol Rep 2019; 41: 801-10.
20. Díaz Del Arco C, Garré P, Molina Roldán E, Lorca V, Cerón Nieto MA, Fernández Aceñero MJ. MUC1 expression in colorectal carcinoma: clinicopathological correlation and prognostic significance. Rev Esp Patol 2018; 51: 204-9.
21. Kashiwagi H, Kijima H, Dowaki S, et al. MUCIN 1 and MUC2 expression in human gallbladder carcinoma: a clinicopathological study and relationship with prognosis. Oncol Rep 2001; 8: 485-9.
22. Song ZB, Gao SS, Yi XN, et al. Expression of MUCIN 1 in esophageal squamous-cell carcinoma and its relationship with prognosis of patients from Linzhou city, a high incidence area of northern China. World J Gastroenterol 2003; 9: 404-7.
23. Sun ZG, Yu L, Gao W, Wang Z, Zhu LM. Clinical and prognostic significance of MUC1 expression in patients with esophageal squamous cell carcinoma after radical resection Saudi J Gastroenterol 2018; 24: 165-70.
24. Nagatani S, Shimada Y, Sato F, Watanabe G, Maeda M, Kaganol J. Expression of E-cadherin, cyclin D1, matrix metalloproteinase 9, and vascular endothelial growth factor in primary tumor of esophageal squamous cell carcinoma does not predict lymph node micrometastasis. Esophagus 2005; 2: 71-5.
25. Gusterson B. Are micrometastases clinically relevant? Br J Hosp Med 1992; 47: 247-8.
26. Jiao X, Krasna MJ. Clinical significance of micrometastasis in lung and esophageal cancer: a new paradigm in thoracic oncology. Ann Thorac Surg 2002; 74: 278-84.
27. Nosotti M, Falleni M, Palleschi A, et al. Quantitative real-time polymerase chain reaction detection of lymph node lung cancer micrometastasis using carcinoma-antigenic antigen marker. Chest 2005; 128: 1539-44.
28. Salerno CT, Frizelle S, Niehans GA, et al. Detection of occult micrometastases in non-small cell lung carcinoma by reverse transcriptase-polymerase chain reaction. J Thorac Oncol 1998; 113: 256-32.
29. Zhang T, Zhang BN, Zhang HT, Sun YT. Detection of micrometastases in sentinel lymph nodes of breast cancer. Zhonghua Zhong Liu Za Zhi 2007; 29: 116-8.
30. Sun ZG, Wang Z. Clinical study on lymph node metastatic recurrence in patients with N0 esophageal squamous cell cancer. Dis Esophagus 2011; 24: 182-8.